http://www.amylin.com http://finance.yahoo.com/q/pr?s=AMLN http://www.form4oracle.com/company?cik=0000881464&ticker=amln
Amylin Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for diabetes, obesity, and other diseases in the United States. It sells BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection for the treatment of patients with Type II diabetes. The company also has research and development programs in the therapeutic areas of diabetes and obesity, including exenatide once weekly; Nasal Exenatide, a nasal spray formulation of exenatide for diabetes; Pramlintide and PYY 3-36 for the treatment of obesity; Leptin for the treatment of obesity and lipodystrophy; Pramlintide-Metreleptin combination product candidate for overweight or obese subjects; and second generation Amylinomimetic for weight loss. It sells its products to healthcare providers, managed healthcare organizations, wholesalers and pharmacies, government purchasers, and other third-party payors. The company has collaboration agreements with Eli Lilly and Company, as well as with Alkermes, Inc. to develop exenatide once weekly for diabetes; a contract research arrangement with Kelaroo, Inc. for the commercialization of Kelaroo's SeqR technology that is used for peptide hormone identification and optimization; a joint research collaboration agreement with BioSeek, Inc. for discovery and development of novel peptide therapeutics for inflammatory conditions; and a joint research collaboration agreement with Xenome, Ltd. for discovery and development of novel peptide hormones for a range of metabolic and musculoskeletal diseases. It also has a collaboration with Pacira Pharmaceuticals, Inc. for the development of sustained release injectable products based on the DepoFoam technology platform. Amylin Pharmaceuticals was founded in 1987 and is based in San Diego, California.